+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bullous pemphigoid Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Bullous pemphigoid Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Bullous pemphigoid Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6011507
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bullous pemphigoid Market grew from USD 358.38 million in 2024 to USD 379.75 million in 2025. It is expected to continue growing at a CAGR of 5.91%, reaching USD 505.98 million by 2030.

Bullous pemphigoid represents a challenging autoimmune blistering disorder most prevalent among the elderly, imposing significant clinical and economic burdens worldwide. Characterized by tense blisters and intense pruritus, this condition often requires prolonged immunosuppressive therapy and vigilant monitoring to prevent complications. In recent years, advancements in diagnostic techniques, including immunofluorescence and serological assays, have refined disease detection and classification, enabling personalized treatment regimens. Nevertheless, management strategies vary widely across treatment centers and geographic regions, underscoring the need for comprehensive market insights. This executive summary synthesizes critical findings on therapeutic modalities, regulatory landscapes, tariff impacts, and competitive dynamics. It also illuminates emerging trends that promise to reshape patient outcomes and guide strategic investments. As stakeholders navigate evolving clinical and commercial environments, this concise yet thorough analysis delivers clarity, equipping decision-makers with the knowledge required to optimize resource allocation and accelerate innovation in bullous pemphigoid care.

Transformative Shifts Reshaping Diagnosis and Treatment

Over the past decade, the bullous pemphigoid market has undergone transformative shifts driven by breakthroughs in biologic therapies, digital health integration, and regulatory modernization. Novel monoclonal antibodies targeting key inflammatory mediators have entered late-stage clinical trials, offering potential alternatives to long-standing corticosteroid regimens. Simultaneously, teledermatology platforms have expanded access to expert consultation, enabling early intervention and improving patient adherence. Regulatory authorities have streamlined approval pathways for orphan and rare disease indications, accelerating time to market for innovative agents. Moreover, real-world evidence initiatives are generating longitudinal safety and efficacy data, informing guideline revisions and payer coverage decisions. These converging trends signal a pivotal moment for stakeholders: the opportunity to harness scientific advancements, leverage digital tools, and navigate evolving policy frameworks to deliver superior care and capture emerging market value.

Cumulative Effects of U.S. Tariffs on Supply Chain and Pricing

The introduction of revised United States tariffs in 2025 has exerted a cumulative impact on the bullous pemphigoid supply chain and pricing dynamics. Increased duties on imported active pharmaceutical ingredients have elevated manufacturing costs for both established immunosuppressants and next-generation biologics, prompting manufacturers to reassess sourcing strategies. In response, some companies have expanded domestic production capabilities to mitigate tariff exposure and preserve margins. Meanwhile, payers and health systems face higher drug acquisition expenses, intensifying scrutiny of cost-effectiveness and compelling pharmaceutical firms to pursue value-based contracts. Patient access programs have adapted by optimizing copay assistance and establishing tiered formularies. Collectively, these shifts underscore the critical importance of resilient supply chains, strategic procurement, and adaptive pricing models to sustain market growth under the new tariff regime.

Deep Dive into Segmentation Drivers and Patient Profiles

Analysis of market segments reveals distinct trends across disease type, severity, administration route, drug class, care settings, treatment modalities, patient demographics, and healthcare delivery models. Childhood and gestational bullous pemphigoid, though rare, are driving research into age-specific safety profiles, while generalized and localized forms continue to command the largest therapeutic share. Mild cases are managed predominantly with topical corticosteroids, whereas moderate and severe presentations increasingly rely on systemic immunosuppressants or biologics. Within administration modes, oral formulations-particularly tablets and capsules-offer patient convenience, yet emerging demand for injectables and infusions reflects the shift toward targeted biologic therapies. The drug class landscape is evolving: corticosteroids remain foundational, but biologics and immunomodulators are expanding their foothold. Dermatology clinics and hospitals constitute primary end-user channels, with homecare settings gaining traction amid patient preference for self-administration. Anti-inflammatory steroid therapy retains prominence, although growing pipelines in novel biologics and immunomodulatory agents promise to diversify treatment options. Demographically, geriatric patients represent the highest prevalence cohort, but pediatric and adult populations underscore the need for adaptable regimens. Healthcare facilities split between private and public sectors underscore varied reimbursement and access frameworks across markets.

Regional Market Dynamics and Access Pathways

Regional analysis highlights varied market trajectories shaped by regulatory environments, infrastructure maturity, and patient access initiatives. In the Americas, robust reimbursement schemes and high adoption rates of advanced therapies fuel market expansion, with the United States leading in clinical trial activity and drug launches. Europe, the Middle East & Africa exhibit heterogenous growth: Western European markets benefit from well-established rare disease frameworks, whereas emerging economies grapple with budget constraints and uneven specialty care distribution. In the Asia-Pacific region, rising healthcare investments, expanding dermatology networks, and government initiatives to bolster local manufacturing are accelerating both generics and branded biologic uptake. Cross-border collaborations and licensing agreements are particularly prevalent in Asia-Pacific, underscoring the strategic importance of aligning with regional partners to navigate regulatory complexities and optimize market entry.

Competitive Landscape and Strategic Positioning of Key Players

The competitive landscape features established pharmaceutical leaders and focused biotech innovators pursuing differentiated strategies. AbbVie’s broad immunology portfolio and strategic acquisitions reinforce its position in the corticosteroid and biologic arenas. Alexion Pharmaceuticals leverages complement pathway expertise to explore novel indications beyond classical immunosuppressants. Almirall’s dermatology specialization drives targeted product development, while Amgen and AstraZeneca invest in antibody engineering to enhance biologic efficacy. Biogen’s immunotherapy research dovetails with emerging pipeline candidates, parallel to Bristol-Myers Squibb’s focus on immune checkpoint modulation. Dermira’s targeted topical programs and Eli Lilly and Company’s autoimmune inflammation expertise highlight diversified approaches. F. Hoffmann-La Roche and Johnson & Johnson capitalize on global manufacturing networks, whereas GlaxoSmithKline explores combination regimens to optimize patient response. Horizon Therapeutics and Merck & Co. prioritize rare disease frameworks, and Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical Company, and UCB S.A. drive collaborative ventures and licensing deals to expand geographic reach and enrich therapeutic offerings. Collectively, these players are reshaping the market through pipeline innovation, strategic partnerships, and targeted commercialization strategies.

Actionable Recommendations for Maximizing Market Potential

To capitalize on emerging opportunities, industry leaders must enhance agility across R&D, manufacturing, and market access functions. First, prioritizing investment in next-generation biologics and novel immunomodulators will differentiate portfolios and address unmet patient needs. Second, fostering collaborative research consortia with academic institutions and CRO partners can accelerate clinical development and reduce time to approval. Third, building robust domestic and regional manufacturing capabilities will mitigate tariff pressures and ensure uninterrupted supply. Fourth, implementing adaptive pricing and reimbursement models-such as outcome-based contracts-will align stakeholder incentives and secure formulary inclusion. Fifth, leveraging digital platforms for remote patient management and real-world evidence collection will optimize adherence and strengthen payer value propositions. Finally, establishing patient support initiatives that encompass education, financial assistance, and care coordination will enhance engagement and long-term outcomes.

Conclusion and Strategic Outlook

Bullous pemphigoid represents a dynamic and evolving therapeutic domain driven by scientific innovation, policy shifts, and competitive ingenuity. As tariffs reshape supply chain economics and segmentation trends illuminate diverse patient needs, success will hinge on integrating cross-functional strategies that balance innovation with operational resilience. Regional nuances in access pathways and payer frameworks demand tailored market entry and commercialization plans. Meanwhile, the intensifying competitive landscape underscores the value of strategic alliances, targeted R&D investments, and patient-centric programs. By harnessing these insights, stakeholders can navigate complexity, drive clinical impact, and unlock sustainable growth in the bullous pemphigoid market.

Market Segmentation & Coverage

This research report categorizes the Bullous pemphigoid Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Childhood Bullous Pemphigoid
  • Generalized Bullous Pemphigoid
  • Gestational Bullous Pemphigoid
  • Localized Bullous Pemphigoid
  • Mild Bullous Pemphigoid
  • Moderate Bullous Pemphigoid
  • Severe Bullous Pemphigoid
  • Oral Administration
    • Capsules
    • Liquids
    • Tablets
  • Parenteral Administration
    • Future Sub-Segmentation Possible: Infusions
    • Injectables
  • Topical Administration
    • Creams
    • Future Sub-Segmentation Possible: Sprays
    • Gels
    • Lotions
    • Ointments
  • Antibiotics
  • Biologics
  • Corticosteroids
    • Oral Corticosteroids
    • Topical Corticosteroids
  • Immunosuppressants
  • Dermatology Clinics
  • Homecare Settings
  • Hospitals
  • Anti-Inflammatory Treatment
    • Steroid Therapy
  • Emerging Therapies
    • Future Sub-Segmentation Possible: Novel Biologic Therapies
  • Immunomodulatory Treatment
  • Symptomatic Supportive Care
    • Antihistamines
    • Emollients
  • Age
    • Adult
    • Geriatric
    • Pediatric
  • Gender
    • Female
    • Male
  • Private Healthcare Settings
  • Public Healthcare Settings

This research report categorizes the Bullous pemphigoid Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Bullous pemphigoid Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie
  • Alexion Pharmaceuticals
  • Almirall
  • Amgen
  • AstraZeneca
  • Biogen
  • Bristol-Myers Squibb
  • Dermira
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Horizon Therapeutics
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Sanofi
  • Takeda Pharmaceutical Company
  • UCB S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bullous pemphigoid Market, by Type
8.1. Introduction
8.2. Childhood Bullous Pemphigoid
8.3. Generalized Bullous Pemphigoid
8.4. Gestational Bullous Pemphigoid
8.5. Localized Bullous Pemphigoid
9. Bullous pemphigoid Market, by Clinical Severity
9.1. Introduction
9.2. Mild Bullous Pemphigoid
9.3. Moderate Bullous Pemphigoid
9.4. Severe Bullous Pemphigoid
10. Bullous pemphigoid Market, by Mode of Administration
10.1. Introduction
10.2. Oral Administration
10.2.1. Capsules
10.2.2. Liquids
10.2.3. Tablets
10.3. Parenteral Administration
10.3.1. Future Sub-Segmentation Possible: Infusions
10.3.2. Injectables
10.4. Topical Administration
10.4.1. Creams
10.4.2. Future Sub-Segmentation Possible: Sprays
10.4.3. Gels
10.4.4. Lotions
10.4.5. Ointments
11. Bullous pemphigoid Market, by Drug Class
11.1. Introduction
11.2. Antibiotics
11.3. Biologics
11.4. Corticosteroids
11.4.1. Oral Corticosteroids
11.4.2. Topical Corticosteroids
11.5. Immunosuppressants
12. Bullous pemphigoid Market, by End User
12.1. Introduction
12.2. Dermatology Clinics
12.3. Homecare Settings
12.4. Hospitals
13. Bullous pemphigoid Market, by Treatment
13.1. Introduction
13.2. Anti-Inflammatory Treatment
13.2.1. Steroid Therapy
13.3. Emerging Therapies
13.3.1. Future Sub-Segmentation Possible: Novel Biologic Therapies
13.4. Immunomodulatory Treatment
13.5. Symptomatic Supportive Care
13.5.1. Antihistamines
13.5.2. Emollients
14. Bullous pemphigoid Market, by Patient Demographics
14.1. Introduction
14.2. Age
14.2.1. Adult
14.2.2. Geriatric
14.2.3. Pediatric
14.3. Gender
14.3.1. Female
14.3.2. Male
15. Bullous pemphigoid Market, by Healthcare Setting
15.1. Introduction
15.2. Private Healthcare Settings
15.3. Public Healthcare Settings
16. Americas Bullous pemphigoid Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Bullous pemphigoid Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Bullous pemphigoid Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AbbVie
19.3.2. Alexion Pharmaceuticals
19.3.3. Almirall
19.3.4. Amgen
19.3.5. AstraZeneca
19.3.6. Biogen
19.3.7. Bristol-Myers Squibb
19.3.8. Dermira
19.3.9. Eli Lilly and Company
19.3.10. F. Hoffmann-La Roche
19.3.11. GlaxoSmithKline
19.3.12. Horizon Therapeutics
19.3.13. Johnson & Johnson
19.3.14. Merck & Co.
19.3.15. Novartis
19.3.16. Pfizer
19.3.17. Regeneron Pharmaceuticals
19.3.18. Sanofi
19.3.19. Takeda Pharmaceutical Company
19.3.20. UCB S.A.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. BULLOUS PEMPHIGOID MARKET MULTI-CURRENCY
FIGURE 2. BULLOUS PEMPHIGOID MARKET MULTI-LANGUAGE
FIGURE 3. BULLOUS PEMPHIGOID MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. BULLOUS PEMPHIGOID MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. BULLOUS PEMPHIGOID MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BULLOUS PEMPHIGOID MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CHILDHOOD BULLOUS PEMPHIGOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GENERALIZED BULLOUS PEMPHIGOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GESTATIONAL BULLOUS PEMPHIGOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY LOCALIZED BULLOUS PEMPHIGOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MILD BULLOUS PEMPHIGOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MODERATE BULLOUS PEMPHIGOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERE BULLOUS PEMPHIGOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FUTURE SUB-SEGMENTATION POSSIBLE: INFUSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FUTURE SUB-SEGMENTATION POSSIBLE: SPRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY LOTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY STEROID THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FUTURE SUB-SEGMENTATION POSSIBLE: NOVEL BIOLOGIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOMODULATORY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY EMOLLIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HEALTHCARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HEALTHCARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 121. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 123. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 129. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 133. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 134. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 135. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 136. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 137. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 208. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 209. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 210. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 216. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 218. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 219. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 220. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 221. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 222. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 223. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 224. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 225. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 226. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 227. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 233. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 235. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 236. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 237. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 238. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 239. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 240. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 241. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 260. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 261. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 267. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 269. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 270. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 271. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 272. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 273. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 274. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 275. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 303. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 304. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 305. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 306. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 307. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 308. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 309. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 317. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 318. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 320. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY ANTI-INFLAMMATORY TREATMENT, 2018-2030 (USD MILLION)
TABLE 321. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY EMERGING THERAPIES, 2018-2030 (USD MILLION)
TABLE 322. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY SYMPTOMATIC SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 323. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 324. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 325. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 326. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 327. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 328. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICAL SEVERITY, 2018-2030 (USD MILLION)
TABLE 329. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 331. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 332. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 334. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 335. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 336. SOUTH KOREA BULLOUS PEMPH

Companies Mentioned

  • AbbVie
  • Alexion Pharmaceuticals
  • Almirall
  • Amgen
  • AstraZeneca
  • Biogen
  • Bristol-Myers Squibb
  • Dermira
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Horizon Therapeutics
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Sanofi
  • Takeda Pharmaceutical Company
  • UCB S.A.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Interleukin 13 Inhibitors - Pipeline Insight, 2025 - Product Image

Interleukin 13 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Pemphigus Vulgaris (PV) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Pemphigus Vulgaris (PV) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 97 Pages
  • Global
From
Behcet Disease Drug Market by Drug Type, Route of Administration, End User, Drug Class, Stage of Disease, Distribution Channel - Global Forecast 2025-2030 - Product Image

Behcet Disease Drug Market by Drug Type, Route of Administration, End User, Drug Class, Stage of Disease, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Alopecia Drugs Market by Drug (Anthralin, Antiandrogens, Finasteride), Disease Area (Alopecia Areata, Androgenetic Alopecia, Cicatricial Alopecia), Administration Route, Patient Demographics, Distribution Channel, Gender - Global Forecast 2025-2030 - Product Image

Alopecia Drugs Market by Drug (Anthralin, Antiandrogens, Finasteride), Disease Area (Alopecia Areata, Androgenetic Alopecia, Cicatricial Alopecia), Administration Route, Patient Demographics, Distribution Channel, Gender - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.